Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Mannitol × Clear all

Phase

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Supratentorial Neoplasms 2 Oligodendroglioma 2 Medulloblastoma 2 Kidney Neoplasms 2 Central Nervous System Neoplasms 2 Brain Neoplasms 2 Astrocytoma 2 Urinary Bladder Neoplasms 1 Stomatitis 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Postoperative Complications 1 Optic Nerve Glioma 1 Neuroectodermal Tumors, Primitive 1 Neoplasms, Germ Cell and Embryonal 1 Nasopharyngeal Carcinoma 1 Hemorrhage 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Familial ependymoma 1 Drug-Related Side Effects and Adverse Reactions 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

Trastuzumab 520 Paclitaxel 472 Cyclophosphamide 467 Docetaxel 411 Capecitabine 348 Letrozole 309 Fulvestrant 268 Doxorubicin 245 Tamoxifen 228 Carboplatin 224 Anastrozole 197 Radiotherapy 193 exemestane 186 Epirubicin 170 Bevacizumab 166 palbociclib 149 Lapatinib 145 Vinorelbine 143 pertuzumab 141 Gemcitabine 138 pembrolizumab 136 Surveys and Questionnaires 118 Exercise 110 Magnetic Resonance Spectroscopy 109 eribulin 103 Fluorouracil 101 Albumin-Bound Paclitaxel 100 Blood Specimen Collection 96 130-nm albumin-bound paclitaxel 90 Everolimus 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06768268 2025-04-16

ICGMV

National Taiwan University Hospital

Phase 1/2 Enrolling by invitation

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡